Brastianos, Priscilla K. http://orcid.org/0000-0003-4470-8425
Kim, Albert E. http://orcid.org/0000-0003-2359-6209
Wang, Nancy
Lee, Eudocia Q.
Ligibel, Jennifer
Cohen, Justine V.
Chukwueke, Ugonma N.
Mahar, Maura
Oh, Kevin
White, Michael D.
Shih, Helen A.
Forst, Deborah
Gainor, Justin F. http://orcid.org/0000-0001-8697-4081
Heist, Rebecca S.
Gerstner, Elizabeth R.
Batchelor, Tracy T.
Lawrence, Donald
Ryan, David P.
Iafrate, A. John
Giobbie-Hurder, Anita
Santagata, Sandro http://orcid.org/0000-0002-7528-9668
Carter, Scott L.
Cahill, Daniel P.
Sullivan, Ryan J. http://orcid.org/0000-0001-5344-6645
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA227156-01, 1R01CA244975-01, 1R01CA244975-01, 1R01CA227156-01, 1R01CA244975-01)
Breast Cancer Research Foundation
American Brain Tumor Association
Article History
Received: 29 September 2020
Accepted: 16 March 2021
First Online: 8 April 2021
Competing interests
: P.K.B. has consulted for Tesaro, Voyager Therapeutics, AngioChem, Genentech/Roche, ElevateBio, SK Life Science, Dantari, Pfizer and Lilly; has received research funding (to Massachusetts General Hospital) from Merck, Mirati, Lilly, BMS and Pfizer; and has received honoraria from Merck and Genentech/Roche. N.W. has received compensation from Seattle Genetics and Wolters Kluwer; and has research funding (to institution, not self) from Merck. E.Q.L. has received royalties from Wolters Kluwer (UpToDate) and has consulted for Lilly. J.V.C. has received consulting fees from Sanofi/Genzyme and BMS. H.A.S. serves on the Board of Directors for the Radiosurgery Society and has received compensation from Wolters Kluwer (UpToDate). D.F. has stock ownership (<$10,000) in Eli Lilly. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, AstraZeneca, Pfizer, Novartis, Merck, and GlydeBio; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals. R.S.H. has received consulting honoraria from Novartis, Daichii Sankyo, EMD Serono, Boehringer Ingelheim, Tarveda, Apollomics; and has research funding (to institution, not to self) from Agios, Abbvie, Daichii Sankyo, Novartis, Lilly, Mirati, Corvus, Genentech Roche, Exelixis, Turning Point. D.P.R. holds equity in MPM Capital and Acworth Pharmaceuticals; has served as a paid consultant and/or on an advisory board for MPM Capital, Oncorus, Gritstone Oncology, Maverick Therapeutics, and Boehringer Ingelheim; and has received compensation from Johns Hopkins University Press, Wolters Kluwer (UpToDate), and McGraw Hill. A.J.I. holds equity in Invitae, and has consulted for Paige.AI, Kinnate, Repare, and Oncoclinicas Brasil. S.S. has consulted for RareCyte, Inc. D.P.C. has consulted for Lilly, GSK, and Boston Pharmaceuticals and has received travel/speaking fees from Merck. R.J.S. has received research funding from Amgen and Merck and served as a paid consultant and/or on an advisory board for Array BioPharma, Amgen, Asana BioSciences, AstraZeneca, BMS, Compugen, Eisai, Genentech, Merck, Novartis, OncoSec, Pfizer and Replimune.